Pancreatic cancer refers to the growth of a malignant tumor in the exocrine parts of the pancreas, such as the head, body, tail, and the ampulla region. In recent years, the worldwide incidence of pancreatic cancer has increased. In China, its incidence has increased by a factor of 6 in the past 20 years. Patients diagnosed with pancreatic cancer have a poor prognosis: 80% die one year after having been diagnosed, and only 10% survive five years after surgery. Pancreatic cancer is rarely diagnosed in early stages and progresses rapidly. At present, no effective drugs are currently available in modern oncology practice, and standard radiotherapy and chemotherapy are of marginal benefit, whereas other modalities, such as photodynamic therapy and immunotherapy. are still under investigation. Once pancreatic cancer is diagnosed, 80% of the patients do not fulfill the criteria for surgery. In the event where surgery is possible, relapses and metastasis development are common. Consequently, the five-year survival rate is less than 25%, and the one-year survival rate of patients with advanced disease is less than 10%. Currently, median survival time of patient with pancreatic cancer remains less than five months. In the absence of effective standard therapy, traditional and complementary medicine remain widely used, in particular in Chinese oncology practice.